The Anglo-Swedish pharmaceutical group Astrazeneca is developing treatment against COVID-19. It is a treatment with antibodies whose trials started and delivered their first results.
The group, thus, announced, today, Friday, August 20, 2021 on Friday, 2021, encouraging results for this treatment, which according to him makes it possible to greatly reduce the risk of developing a symptomatic form of the disease in fragile patients.
Already tested before, the treatment in question had not shown its effectiveness on people already exposed to the virus, but by administering it before a person is in contact with the virus, the results are positive, explains Astrazeneca in a press release.
The treatment would reduce the risk of developing a symptomatic form by 77%, according to clinical trials carried out in Spain, France, Belgium, the United Kingdom and the United States and which focused on 5,197 participants, 75% of which had co-morbidities.
Astrazeneca even indicates that there was no severe case of COVID-19 or death, stressing that it would file a file with the health authorities to obtain emergency use or validation under conditions of treatment.
